search
Back to results

Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes

Primary Purpose

Diabetes Mellitus, Type 2

Status
Recruiting
Phase
Not Applicable
Locations
Brazil
Study Type
Interventional
Intervention
Operative group of nutrition education
Sponsored by
Hospital de Clinicas de Porto Alegre
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring Glycated Hemoglobin A, Food and Nutrition Education, Feeding Behavior

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

- Adult patients with a previous diagnosis of type 2 diabetes mellitus

Exclusion Criteria:

  • Patients with other types of diabetes
  • With HbA1C within the therapeutic target or with values greater than 12%
  • Severe neuropathy
  • Chronic kidney disease [glomerular filtration rate <30mL/min/1.73m²]
  • Life expectancy <6 months
  • Chemical dependence/alcoholism or use of antipsychotics
  • Autoimmune disease or chronic steroid use
  • Gastroparesis
  • Pregnant or lactating women
  • Patients who have had an Episode of Acute Coronary Syndrome (ACS) in the last 60 days
  • Wheelchair users
  • Cognitive, neurological or psychiatric condition

Sites / Locations

  • Hospital de Clinicas de Porto AlegreRecruiting
  • Universidade Federal do Rio Grande do SulRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Intervention

Control (usual treatment)

Arm Description

Intervention: The intervention will be carried out with operational nutritional education groups. Three meetings will be held, each meeting lasting one hour, weekly or fortnightly (according to the availability of the patient). The following foods foods proposed foods: Meeting 1 = education on classification labels and proposed foods proposed foods (education on classification labels and substitution of Brazilian foods), in this guide meeting the proposal is processed or ultra-processed by an in natura food or minimally processed; Meeting 2 = assembly of the healthy dish (food portions, food index and glycemic load, food clothes), the proposal in this meeting is the assembly of the complete dish in the meals eaten throughout the day; and Encounter 3 = hunger and satiety (aiming to increase the perception of hunger and satiety signals), encounter as a task to be accomplished.

Patients will follow the usual follow-up offered at the HCPA nutrition and diabetes outpatient clinic: individual consultations every three or four months (three to four meetings a year). These consultations will be carried out in the form of nutritional counseling, where up to five combinations for dietary changes are agreed with the patient. In each service, after nutritional anamnesis, adherence to combinations for lifestyle changes is verified, as well as possible barriers and motivations to continue the counseling process.

Outcomes

Primary Outcome Measures

Change in baseline HbA1C at 4 months
The Glycated Hemoglobin test (high precision chromatography on a Merck-Hitachi 9100 device with reference values of 4.8-6.0%) will be performed at the Clinical Pathology Laboratory of the Hospital de Clínicas de Porto Alegre (HCPA) by means of blood sample. The patient will be instructed to fast for 12 hours.
Change in baseline HbA1C at 8 months
The Glycated Hemoglobin test (high precision chromatography on a Merck-Hitachi 9100 device with reference values of 4.8-6.0%) will be performed at the Clinical Pathology Laboratory of the Hospital de Clínicas de Porto Alegre (HCPA) by means of blood sample. The patient will be instructed to fast for 12 hours.
Change in baseline HbA1C at 12 months
The Glycated Hemoglobin test (high precision chromatography on a Merck-Hitachi 9100 device with reference values of 4.8-6.0%) will be performed at the Clinical Pathology Laboratory of the Hospital de Clínicas de Porto Alegre (HCPA) by means of blood sample. The patient will be instructed to fast for 12 hours.
Change in diabetic retinopathy and baseline diabetic kidney disease at 12 months
Diabetes kidney disease and diabetic retinopathy will be collected from patients' electronic medical records at baseline and at the end of the study (12 months).

Secondary Outcome Measures

Change in basal body mass index at 4 months
Anthropometric measurements will be used to assess nutritional status and will include weight (with light clothes and without shoes) and height. For such measurements, an anthropometric scale and a fixed wall stadiometer will be used. BMI will be calculated from the formula weight (kg)/height2) and will be considered healthy weight (therapeutic target) when <25 kg/m2 for adults and <27 kg/m2 for the elderly.
Change in basal body mass index at 8 months
Anthropometric measurements will be used to assess nutritional status and will include weight (with light clothes and without shoes) and height. For such measurements, an anthropometric scale and a fixed wall stadiometer will be used. BMI will be calculated from the formula weight (kg)/height2) and will be considered healthy weight (therapeutic target) when <25 kg/m2 for adults and <27 kg/m2 for the elderly.
Change in basal body mass index at 12 months
Anthropometric measurements will be used to assess nutritional status and will include weight (with light clothes and without shoes) and height. For such measurements, an anthropometric scale and a fixed wall stadiometer will be used. BMI will be calculated from the formula weight (kg)/height2) and will be considered healthy weight (therapeutic target) when <25 kg/m2 for adults and <27 kg/m2 for the elderly.
Change in basal metabolic control at 4 months
The analyzes will be carried out at the Clinical Pathology Laboratory of the Hospital de Clínicas de Porto Alegre and will comprise: fasting plasma glucose (measured by the enzymatic glucose-peroxidase method - Biodiagnostic Kit), total cholesterol (colorimetric enzymatic method), HDL cholesterol (colorimetric reaction enzyme analysis, methods described by Farish and modified Fletcher) and serum triglycerides (colorimetric enzymatic method using a commercial kit, as described by McGowan). LDL cholesterol will be calculated using the Friedewald formula for patients with serum triglycerides below 400 mg/dL. The patient will be instructed to fast for 12 hours. Fasting glucose values between 80 - 130 mg/dL, HbA1c <7%, LDL-cholesterol <100 mg/dL and triglycerides <150 mg/dL will be considered within the recommended therapeutic target. Patients with HbA1c <7.0% (adults) and <7.5% (elderly) will be considered with good glycemic control.
Change in basal metabolic control at 8 months
The analyzes will be carried out at the Clinical Pathology Laboratory of the Hospital de Clínicas de Porto Alegre and will comprise: fasting plasma glucose (measured by the enzymatic glucose-peroxidase method - Biodiagnostic Kit), total cholesterol (colorimetric enzymatic method), HDL cholesterol (colorimetric reaction enzyme analysis, methods described by Farish and modified Fletcher) and serum triglycerides (colorimetric enzymatic method using a commercial kit, as described by McGowan). LDL cholesterol will be calculated using the Friedewald formula for patients with serum triglycerides below 400 mg/dL. The patient will be instructed to fast for 12 hours. Fasting glucose values between 80 - 130 mg/dL, HbA1c <7%, LDL-cholesterol <100 mg/dL and triglycerides <150 mg/dL will be considered within the recommended therapeutic target. Patients with HbA1c <7.0% (adults) and <7.5% (elderly) will be considered with good glycemic control.
Change in basal metabolic control at 12 months
The analyzes will be carried out at the Clinical Pathology Laboratory of the Hospital de Clínicas de Porto Alegre and will comprise: fasting plasma glucose (measured by the enzymatic glucose-peroxidase method - Biodiagnostic Kit), total cholesterol (colorimetric enzymatic method), HDL cholesterol (colorimetric reaction enzyme analysis, methods described by Farish and modified Fletcher) and serum triglycerides (colorimetric enzymatic method using a commercial kit, as described by McGowan). LDL cholesterol will be calculated using the Friedewald formula for patients with serum triglycerides below 400 mg/dL. The patient will be instructed to fast for 12 hours. Fasting glucose values between 80 - 130 mg/dL, HbA1c <7%, LDL-cholesterol <100 mg/dL and triglycerides <150 mg/dL will be considered within the recommended therapeutic target. Patients with HbA1c <7.0% (adults) and <7.5% (elderly) will be considered with good glycemic control.
Change in baseline blood pressure at 4 months
Three blood pressure measurements will be performed with a Digital Blood Pressure Monitor Omron sphygmomanometer model HEM-705CP, with an interval of one minute, with the patient sitting down after five minutes of rest, using a cuff of the appropriate size for the arm diameter.
Change in baseline blood pressure at 8 months
Three blood pressure measurements will be performed with a Digital Blood Pressure Monitor Omron sphygmomanometer model HEM-705CP, with an interval of one minute, with the patient sitting down after five minutes of rest, using a cuff of the appropriate size for the arm diameter.
Change in baseline blood pressure at 12 months
Three blood pressure measurements will be performed with a Digital Blood Pressure Monitor Omron sphygmomanometer model HEM-705CP, with an interval of one minute, with the patient sitting down after five minutes of rest, using a cuff of the appropriate size for the arm diameter.
Change in baseline waist circumference at 4 months
The waist circumference measurement will be taken at the midpoint between the last rib and the iliac crest. For this measurement, an inelastic fiberglass measuring tape will be used. For classification, cutoff measurements < 94cm for men and <80cm for women will be used.
Change in baseline waist circumference at 8 months
The waist circumference measurement will be taken at the midpoint between the last rib and the iliac crest. For this measurement, an inelastic fiberglass measuring tape will be used. For classification, cutoff measurements < 94cm for men and <80cm for women will be used.
Change in baseline waist circumference at 12 months
The waist circumference measurement will be taken at the midpoint between the last rib and the iliac crest. For this measurement, an inelastic fiberglass measuring tape will be used. For classification, cutoff measurements < 94cm for men and <80cm for women will be used.

Full Information

First Posted
October 13, 2022
Last Updated
October 24, 2022
Sponsor
Hospital de Clinicas de Porto Alegre
search

1. Study Identification

Unique Protocol Identification Number
NCT05598203
Brief Title
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
Official Title
Effect of the Inclusion of Food Education Groups in the Usual Care of Patients With Type 2 Diabetes Treated at a Specialized Outpatient Clinic: Randomized Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Recruiting
Study Start Date
September 6, 2022 (Actual)
Primary Completion Date
August 30, 2023 (Anticipated)
Study Completion Date
June 30, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hospital de Clinicas de Porto Alegre

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Every year there is an increase in people with diabetes all over the world. Because it is a disease associated with several comorbidities and is increasing, there is a need for more effective treatments. Lifestyle changes combined with medication are the best strategies for the treatment and reduction of comorbidities. Therefore, this study seeks to assess the effect of group nutrition education on metabolic control and diabetes complications compared to usual care. A randomized clinical trial will be conducted with adult patients with a previous diagnosis of type 2 diabetes. Patients will be divided into two groups (intervention: nutritional education; and control: usual care). The outcomes analyzed will be: metabolic control, intuitive food scale, food consumption, body composition and chronic complications of diabetes (diabetic retinopathy and diabetic kidney disease).
Detailed Description
The estimate of patients with diabetes increases every year and for their treatment, a change in lifestyle is essential, so there is a need to seek strategies that increase patient adherence in the long term. Therefore, this study seeks to evaluate the effect of food education with operative groups on metabolic control and diabetes complications in patients with type 2 DM when compared with the usual treatment offered in a specialized nutrition outpatient clinic. An open randomized clinical trial will be performed. Patients = patients with type 2 DM; Intervention = food (nutritional) education based on operative groups; Control = usual care; Outcome/Outcomes = metabolic control, intuitive eating scale, food consumption, body composition and chronic complications of diabetes (diabetic retinopathy and diabetes kidney disease). 116 patients will be needed in each group (1:1), considering a difference in glycated hemoglobin of 0.59 + 1.39% between patients in the intervention group when compared to the control observed in the literature, error Type I error of 5%, Type II error of 20% and a possible loss rate of 30%.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
Keywords
Glycated Hemoglobin A, Food and Nutrition Education, Feeding Behavior

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Each group will be exposed to only one of the factors, diabetes education operative groups or usual individual counseling.
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
232 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intervention
Arm Type
Experimental
Arm Description
Intervention: The intervention will be carried out with operational nutritional education groups. Three meetings will be held, each meeting lasting one hour, weekly or fortnightly (according to the availability of the patient). The following foods foods proposed foods: Meeting 1 = education on classification labels and proposed foods proposed foods (education on classification labels and substitution of Brazilian foods), in this guide meeting the proposal is processed or ultra-processed by an in natura food or minimally processed; Meeting 2 = assembly of the healthy dish (food portions, food index and glycemic load, food clothes), the proposal in this meeting is the assembly of the complete dish in the meals eaten throughout the day; and Encounter 3 = hunger and satiety (aiming to increase the perception of hunger and satiety signals), encounter as a task to be accomplished.
Arm Title
Control (usual treatment)
Arm Type
No Intervention
Arm Description
Patients will follow the usual follow-up offered at the HCPA nutrition and diabetes outpatient clinic: individual consultations every three or four months (three to four meetings a year). These consultations will be carried out in the form of nutritional counseling, where up to five combinations for dietary changes are agreed with the patient. In each service, after nutritional anamnesis, adherence to combinations for lifestyle changes is verified, as well as possible barriers and motivations to continue the counseling process.
Intervention Type
Behavioral
Intervention Name(s)
Operative group of nutrition education
Intervention Description
The intervention will be carried out with operational nutritional education groups. Three meetings will be held, each meeting lasting one hour, weekly or fortnightly (according to the availability of the patient). The following foods foods proposed foods: Meeting 1 = education on classification labels and proposed foods proposed foods (education on classification labels and substitution of Brazilian foods), in this guide meeting the proposal is processed or ultra-processed by an in natura food or minimally processed; Meeting 2 = assembly of the healthy dish (food portions, food index and glycemic load, food clothes), the proposal in this meeting is the assembly of the complete dish in the meals eaten throughout the day; and Encounter 3 = hunger and satiety (aiming to increase the perception of hunger and satiety signals), encounter as a task to be accomplished.
Primary Outcome Measure Information:
Title
Change in baseline HbA1C at 4 months
Description
The Glycated Hemoglobin test (high precision chromatography on a Merck-Hitachi 9100 device with reference values of 4.8-6.0%) will be performed at the Clinical Pathology Laboratory of the Hospital de Clínicas de Porto Alegre (HCPA) by means of blood sample. The patient will be instructed to fast for 12 hours.
Time Frame
From baseline to 4 months
Title
Change in baseline HbA1C at 8 months
Description
The Glycated Hemoglobin test (high precision chromatography on a Merck-Hitachi 9100 device with reference values of 4.8-6.0%) will be performed at the Clinical Pathology Laboratory of the Hospital de Clínicas de Porto Alegre (HCPA) by means of blood sample. The patient will be instructed to fast for 12 hours.
Time Frame
From baseline to 8 months
Title
Change in baseline HbA1C at 12 months
Description
The Glycated Hemoglobin test (high precision chromatography on a Merck-Hitachi 9100 device with reference values of 4.8-6.0%) will be performed at the Clinical Pathology Laboratory of the Hospital de Clínicas de Porto Alegre (HCPA) by means of blood sample. The patient will be instructed to fast for 12 hours.
Time Frame
From baseline to 12 months
Title
Change in diabetic retinopathy and baseline diabetic kidney disease at 12 months
Description
Diabetes kidney disease and diabetic retinopathy will be collected from patients' electronic medical records at baseline and at the end of the study (12 months).
Time Frame
From baseline to 12 months
Secondary Outcome Measure Information:
Title
Change in basal body mass index at 4 months
Description
Anthropometric measurements will be used to assess nutritional status and will include weight (with light clothes and without shoes) and height. For such measurements, an anthropometric scale and a fixed wall stadiometer will be used. BMI will be calculated from the formula weight (kg)/height2) and will be considered healthy weight (therapeutic target) when <25 kg/m2 for adults and <27 kg/m2 for the elderly.
Time Frame
From baseline to 4 months
Title
Change in basal body mass index at 8 months
Description
Anthropometric measurements will be used to assess nutritional status and will include weight (with light clothes and without shoes) and height. For such measurements, an anthropometric scale and a fixed wall stadiometer will be used. BMI will be calculated from the formula weight (kg)/height2) and will be considered healthy weight (therapeutic target) when <25 kg/m2 for adults and <27 kg/m2 for the elderly.
Time Frame
From baseline to 8 months
Title
Change in basal body mass index at 12 months
Description
Anthropometric measurements will be used to assess nutritional status and will include weight (with light clothes and without shoes) and height. For such measurements, an anthropometric scale and a fixed wall stadiometer will be used. BMI will be calculated from the formula weight (kg)/height2) and will be considered healthy weight (therapeutic target) when <25 kg/m2 for adults and <27 kg/m2 for the elderly.
Time Frame
From baseline to 12 months
Title
Change in basal metabolic control at 4 months
Description
The analyzes will be carried out at the Clinical Pathology Laboratory of the Hospital de Clínicas de Porto Alegre and will comprise: fasting plasma glucose (measured by the enzymatic glucose-peroxidase method - Biodiagnostic Kit), total cholesterol (colorimetric enzymatic method), HDL cholesterol (colorimetric reaction enzyme analysis, methods described by Farish and modified Fletcher) and serum triglycerides (colorimetric enzymatic method using a commercial kit, as described by McGowan). LDL cholesterol will be calculated using the Friedewald formula for patients with serum triglycerides below 400 mg/dL. The patient will be instructed to fast for 12 hours. Fasting glucose values between 80 - 130 mg/dL, HbA1c <7%, LDL-cholesterol <100 mg/dL and triglycerides <150 mg/dL will be considered within the recommended therapeutic target. Patients with HbA1c <7.0% (adults) and <7.5% (elderly) will be considered with good glycemic control.
Time Frame
From baseline to 4 months
Title
Change in basal metabolic control at 8 months
Description
The analyzes will be carried out at the Clinical Pathology Laboratory of the Hospital de Clínicas de Porto Alegre and will comprise: fasting plasma glucose (measured by the enzymatic glucose-peroxidase method - Biodiagnostic Kit), total cholesterol (colorimetric enzymatic method), HDL cholesterol (colorimetric reaction enzyme analysis, methods described by Farish and modified Fletcher) and serum triglycerides (colorimetric enzymatic method using a commercial kit, as described by McGowan). LDL cholesterol will be calculated using the Friedewald formula for patients with serum triglycerides below 400 mg/dL. The patient will be instructed to fast for 12 hours. Fasting glucose values between 80 - 130 mg/dL, HbA1c <7%, LDL-cholesterol <100 mg/dL and triglycerides <150 mg/dL will be considered within the recommended therapeutic target. Patients with HbA1c <7.0% (adults) and <7.5% (elderly) will be considered with good glycemic control.
Time Frame
From baseline to 8 months
Title
Change in basal metabolic control at 12 months
Description
The analyzes will be carried out at the Clinical Pathology Laboratory of the Hospital de Clínicas de Porto Alegre and will comprise: fasting plasma glucose (measured by the enzymatic glucose-peroxidase method - Biodiagnostic Kit), total cholesterol (colorimetric enzymatic method), HDL cholesterol (colorimetric reaction enzyme analysis, methods described by Farish and modified Fletcher) and serum triglycerides (colorimetric enzymatic method using a commercial kit, as described by McGowan). LDL cholesterol will be calculated using the Friedewald formula for patients with serum triglycerides below 400 mg/dL. The patient will be instructed to fast for 12 hours. Fasting glucose values between 80 - 130 mg/dL, HbA1c <7%, LDL-cholesterol <100 mg/dL and triglycerides <150 mg/dL will be considered within the recommended therapeutic target. Patients with HbA1c <7.0% (adults) and <7.5% (elderly) will be considered with good glycemic control.
Time Frame
From baseline to 12 months
Title
Change in baseline blood pressure at 4 months
Description
Three blood pressure measurements will be performed with a Digital Blood Pressure Monitor Omron sphygmomanometer model HEM-705CP, with an interval of one minute, with the patient sitting down after five minutes of rest, using a cuff of the appropriate size for the arm diameter.
Time Frame
From baseline to 4 months
Title
Change in baseline blood pressure at 8 months
Description
Three blood pressure measurements will be performed with a Digital Blood Pressure Monitor Omron sphygmomanometer model HEM-705CP, with an interval of one minute, with the patient sitting down after five minutes of rest, using a cuff of the appropriate size for the arm diameter.
Time Frame
From baseline to 8 months
Title
Change in baseline blood pressure at 12 months
Description
Three blood pressure measurements will be performed with a Digital Blood Pressure Monitor Omron sphygmomanometer model HEM-705CP, with an interval of one minute, with the patient sitting down after five minutes of rest, using a cuff of the appropriate size for the arm diameter.
Time Frame
From baseline to 12 months
Title
Change in baseline waist circumference at 4 months
Description
The waist circumference measurement will be taken at the midpoint between the last rib and the iliac crest. For this measurement, an inelastic fiberglass measuring tape will be used. For classification, cutoff measurements < 94cm for men and <80cm for women will be used.
Time Frame
From baseline to 4 months
Title
Change in baseline waist circumference at 8 months
Description
The waist circumference measurement will be taken at the midpoint between the last rib and the iliac crest. For this measurement, an inelastic fiberglass measuring tape will be used. For classification, cutoff measurements < 94cm for men and <80cm for women will be used.
Time Frame
From baseline to 8 months
Title
Change in baseline waist circumference at 12 months
Description
The waist circumference measurement will be taken at the midpoint between the last rib and the iliac crest. For this measurement, an inelastic fiberglass measuring tape will be used. For classification, cutoff measurements < 94cm for men and <80cm for women will be used.
Time Frame
From baseline to 12 months
Other Pre-specified Outcome Measures:
Title
Change in baseline Intuitive eating at 4 months
Description
It will be estimated by the Intuitive Eating Scale-2. It is a 23-item scale, scored from one to five, ranging from "strongly disagree" to "strongly agree", respectively (the higher the score, the greater the intuitive eating). The scale is divided into four components (subscales): Unconditional Permission to Eat; Eating to meet physiological and non-emotional needs; Reconnect with hunger signals to determine when and how much to eat. and Congruence in food choices, allowing for body nutrition. The scale has seven items with negative scores. The evaluation of the scale score is done through the mean or median (depending on the normality of the data). Classifying as individuals who eat less intuitively those who are below this value, and individuals who eat more intuitively who are scoring equal to or above this value. An average or median will be taken for the total score of the scale and for each of the subscales.
Time Frame
From baseline to 4 months
Title
Change in baseline Intuitive eating at 8 months
Description
It will be estimated by the Intuitive Eating Scale-2. It is a 23-item scale, scored from one to five, ranging from "strongly disagree" to "strongly agree", respectively (the higher the score, the greater the intuitive eating). The scale is divided into four components (subscales): Unconditional Permission to Eat; Eating to meet physiological and non-emotional needs; Reconnect with hunger signals to determine when and how much to eat. and Congruence in food choices, allowing for body nutrition. The scale has seven items with negative scores. The evaluation of the scale score is done through the mean or median (depending on the normality of the data). Classifying as individuals who eat less intuitively those who are below this value, and individuals who eat more intuitively who are scoring equal to or above this value. An average or median will be taken for the total score of the scale and for each of the subscales.
Time Frame
From baseline to 8 months
Title
Change in baseline Intuitive eating at 12 months
Description
It will be estimated by the Intuitive Eating Scale-2. It is a 23-item scale, scored from one to five, ranging from "strongly disagree" to "strongly agree", respectively (the higher the score, the greater the intuitive eating). The scale is divided into four components (subscales): Unconditional Permission to Eat; Eating to meet physiological and non-emotional needs; Reconnect with hunger signals to determine when and how much to eat. and Congruence in food choices, allowing for body nutrition. The scale has seven items with negative scores. The evaluation of the scale score is done through the mean or median (depending on the normality of the data). Classifying as individuals who eat less intuitively those who are below this value, and individuals who eat more intuitively who are scoring equal to or above this value. An average or median will be taken for the total score of the scale and for each of the subscales.
Time Frame
From baseline to 12 months
Title
Change in baseline Sarcopenia at 4 months
Description
It will be performed by the SARC-CalF that uses 5 criteria (strength, help to walk, difficulty getting up from a chair, difficulty climbing stairs and falls in the last year), on a scale from 0 to 2 and adding to that the measurement of the circumference of the calf, which receives 0 if it is higher than the cut-off point, or 10 if it is equal to or lower than the cut-off point (≤34 cm for men and ≤33 cm for women). Scores ≥11 are suggestive of sarcopenia. In these cases, muscle strength will be evaluated from the hand grip strength using the Hydraulic Hand Dynamometer. The cutoff points used to identify low muscle strength will be <27 kg in men and <16 kg in women. If low muscle strength, it will be classified as probable sarcopenia. The severity of sarcopenia will be evaluated through the measurement of physical performance by the walk test (walking a distance of 4 meters), if less than 5 seconds, it is classified with low physical performance and with severe sarcopenia.
Time Frame
From baseline to 4 months
Title
Change in baseline Sarcopenia at 8 months
Description
It will be performed by the SARC-CalF that uses 5 criteria (strength, help to walk, difficulty getting up from a chair, difficulty climbing stairs and falls in the last year), on a scale from 0 to 2 and adding to that the measurement of the circumference of the calf, which receives 0 if it is higher than the cut-off point, or 10 if it is equal to or lower than the cut-off point (≤34 cm for men and ≤33 cm for women). Scores ≥11 are suggestive of sarcopenia. In these cases, muscle strength will be evaluated from the hand grip strength using the Hydraulic Hand Dynamometer. The cutoff points used to identify low muscle strength will be <27 kg in men and <16 kg in women. If low muscle strength, it will be classified as probable sarcopenia. The severity of sarcopenia will be evaluated through the measurement of physical performance by the walk test (walking a distance of 4 meters), if less than 5 seconds, it is classified with low physical performance and with severe sarcopenia.
Time Frame
From baseline to 8 months
Title
Change in baseline Sarcopenia at 12 months
Description
It will be performed by the SARC-CalF that uses 5 criteria (strength, help to walk, difficulty getting up from a chair, difficulty climbing stairs and falls in the last year), on a scale from 0 to 2 and adding to that the measurement of the circumference of the calf, which receives 0 if it is higher than the cut-off point, or 10 if it is equal to or lower than the cut-off point (≤34 cm for men and ≤33 cm for women). Scores ≥11 are suggestive of sarcopenia. In these cases, muscle strength will be evaluated from the hand grip strength using the Hydraulic Hand Dynamometer. The cutoff points used to identify low muscle strength will be <27 kg in men and <16 kg in women. If low muscle strength, it will be classified as probable sarcopenia. The severity of sarcopenia will be evaluated through the measurement of physical performance by the walk test (walking a distance of 4 meters), if less than 5 seconds, it is classified with low physical performance and with severe sarcopenia.
Time Frame
From baseline to 12 months

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: - Adult patients with a previous diagnosis of type 2 diabetes mellitus Exclusion Criteria: Patients with other types of diabetes With HbA1C within the therapeutic target or with values greater than 12% Severe neuropathy Chronic kidney disease [glomerular filtration rate <30mL/min/1.73m²] Life expectancy <6 months Chemical dependence/alcoholism or use of antipsychotics Autoimmune disease or chronic steroid use Gastroparesis Pregnant or lactating women Patients who have had an Episode of Acute Coronary Syndrome (ACS) in the last 60 days Wheelchair users Cognitive, neurological or psychiatric condition
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jussara C De Almeida, PhD
Phone
+555133598410
Email
jcalmeida@hcpa.edu.br
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jussara C De Almeida, PhD
Organizational Affiliation
Federal University of Rio Grande do Sul
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital de Clinicas de Porto Alegre
City
Porto Alegre
State/Province
Rio Grande Do Sul
ZIP/Postal Code
90035003
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jussara C De Almeida, PhD
Phone
+555133598410
Email
jcalmeida@hcpa.edu.br
Facility Name
Universidade Federal do Rio Grande do Sul
City
Porto Alegre
State/Province
Rio Grande Do Sul
ZIP/Postal Code
90035003
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jussara C De Almeida, PhD
Phone
+555133598410
Email
jcalmeida@hcpa.edu.br

12. IPD Sharing Statement

Learn more about this trial

Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes

We'll reach out to this number within 24 hrs